ZA200806067B - Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery - Google Patents

Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery

Info

Publication number
ZA200806067B
ZA200806067B ZA200806067A ZA200806067A ZA200806067B ZA 200806067 B ZA200806067 B ZA 200806067B ZA 200806067 A ZA200806067 A ZA 200806067A ZA 200806067 A ZA200806067 A ZA 200806067A ZA 200806067 B ZA200806067 B ZA 200806067B
Authority
ZA
South Africa
Prior art keywords
prophylaxis
complications
receptor antagonists
thrombin receptor
cardiopulmonary surgery
Prior art date
Application number
ZA200806067A
Other languages
English (en)
Inventor
Enrico P Veltri
John T Stony
Berman Gail
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200806067(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200806067B publication Critical patent/ZA200806067B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200806067A 2005-12-22 2008-07-11 Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery ZA200806067B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75324605P 2005-12-22 2005-12-22

Publications (1)

Publication Number Publication Date
ZA200806067B true ZA200806067B (en) 2009-08-26

Family

ID=38218643

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200806067A ZA200806067B (en) 2005-12-22 2008-07-11 Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery

Country Status (11)

Country Link
US (2) US20070202140A1 (de)
EP (1) EP1971336A2 (de)
JP (1) JP2009521472A (de)
CN (1) CN101384259A (de)
AU (1) AU2006331583A1 (de)
BR (1) BRPI0620641A2 (de)
CA (1) CA2634216A1 (de)
NO (1) NO20083236L (de)
TW (1) TW200744593A (de)
WO (1) WO2007075964A2 (de)
ZA (1) ZA200806067B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
AR060354A1 (es) * 2006-04-06 2008-06-11 Schering Corp Terapias de combinacion antagonistas receptor trombina (tra)
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
BRPI0809095A2 (pt) * 2007-03-23 2014-09-09 Schering Corp Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
BRPI0906395A2 (pt) * 2008-01-11 2016-11-01 Eisai R&D Man Co Ltd composição farmacêutica, uso de pelo menos um composto ou um sal farmacologicamente aceitável do mesmo, kit, e, método para tratar ou melhorar as doenças cardíacas
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
CN101554378B (zh) * 2008-04-09 2011-01-12 鲁南制药集团股份有限公司 含有普拉格雷的药物组合物
US20120028976A1 (en) * 2008-11-17 2012-02-02 Larisa Reyderman Pharmacokinetically-based dosing regiments of a thrombin receptor antagonist
DK3127427T3 (da) * 2009-05-29 2020-04-06 Novartis Ag Fremgangsmåder til administration af trombopoietinagonistforbindelser
US8575351B2 (en) 2009-06-04 2013-11-05 Merck Sharp & Dohme Corp. Active metabolite of a thrombin receptor antagonist
JP2012529431A (ja) 2009-06-08 2012-11-22 メルク・シャープ・アンド・ドーム・コーポレーション トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤
US9604971B2 (en) 2013-07-22 2017-03-28 Aralez Pharmaceuticals Trading Dac Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin
EA201890571A1 (ru) * 2015-08-25 2018-10-31 Элнилэм Фармасьютикалз, Инк. Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9)
WO2017181993A1 (zh) * 2016-04-22 2017-10-26 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
WO2020101627A1 (en) * 2018-11-14 2020-05-22 Canakkale Onsekiz Mart Universitesi Rektorlugu A solution developed to be applied to the saphenous vein graft

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3020A (en) * 1843-03-30 Improvement in disengaging horses from carriages
US4015A (en) * 1845-04-26 Hand-loom for weaving figured fabrics
US3021A (en) * 1843-03-30 Stove with elevated ovejst
US4019A (en) * 1845-05-01 Pianoforte
US4017A (en) * 1845-05-01 Reid r
US4000A (en) * 1845-04-16 Combined lock and latch
US2000A (en) * 1841-03-12 Improvement in the manufacture of starch
AU1629383A (en) * 1982-10-02 1984-04-05 Amano Seiyaku K.K. Earthworm tissue protease thrombolytic agents
TW499412B (en) * 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
UA66370C2 (en) * 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
US6613573B1 (en) * 1999-02-22 2003-09-02 Haemoscope Corporation Method and apparatus for monitoring anti-platelet agents
US6630451B1 (en) * 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
AU5895500A (en) * 1999-06-29 2001-01-31 Cor Therapeutics, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
US6515023B2 (en) * 2000-01-31 2003-02-04 Merck & Co., Inc. Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
PE20020235A1 (es) * 2000-06-15 2002-04-02 Schering Corp Derivados de nor-seco himbacina como antagonistas de los receptores de trombina
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040096443A1 (en) * 2002-03-08 2004-05-20 Traynelis Stephen Francis Treatment of neurodegenerative diseases and conditions using par1 antagonists
AU2002331707A1 (en) * 2001-08-20 2003-03-03 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as antithrombotic agents
HUP0500443A3 (en) * 2001-10-18 2009-12-28 Schering Corp Himbacine analogues as thrombin receptor antagonists and pharmaceutical compositions containing them
SI2065384T1 (sl) * 2002-04-16 2011-05-31 Schering Corp Tricikliäśni trombin receptor antagonist
EP1721610B1 (de) * 2004-03-04 2009-05-13 Eisai R&D Management Co., Ltd. Zusammensetzung mit benzamidin-derivat und verfahren zur stabilisierung von benzamidin-derivat
ES2374379T3 (es) * 2005-01-14 2012-02-16 Schering Corporation Síntesis exo y diastereoselectiva de análogos de himbacina.
US20070238674A1 (en) * 2006-04-06 2007-10-11 Veltri Enrico P Tra combination therapies

Also Published As

Publication number Publication date
US20070202140A1 (en) 2007-08-30
NO20083236L (no) 2008-09-22
CN101384259A (zh) 2009-03-11
WO2007075964A2 (en) 2007-07-05
TW200744593A (en) 2007-12-16
WO2007075964A3 (en) 2007-09-20
BRPI0620641A2 (pt) 2011-11-16
US20090062239A1 (en) 2009-03-05
AU2006331583A1 (en) 2007-07-05
EP1971336A2 (de) 2008-09-24
CA2634216A1 (en) 2007-07-05
JP2009521472A (ja) 2009-06-04
WO2007075964A8 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
ZA200806067B (en) Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
ZA200705449B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
TWI365178B (en) Double bond hydroisomerization of butenes
IL194160A0 (en) 2-aminopyridine analogs as glucokinase activators
IL198345A0 (en) New sulfonamide derivatives as bradykinin antagonists
IL222922A0 (en) Neuropilin antagonists
IL196587A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
ZA200902915B (en) Substituted sulfonamide derivatives
GB0607085D0 (en) Novel compositions
EP1781567A4 (de) Calciumhypochloritzusammensetzungen
IL177762A0 (en) Bimatoprost crystalline form i
HU0600809D0 (en) New phenylsulfamoil benzamide derivatives as bradykinin antagonists
HK1137992A1 (en) Sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists
ZA200806065B (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
IL197325A0 (en) Imatinib compositions
HRP20130836T1 (en) New benzamide derivatives as bradykinin antagonists
EP1888618A4 (de) Analoga von glycyl-prolyl-glutamat
IL198542A0 (en) 2-aminoquinolines as 5-ht(5a)receptor antagonists
IL197327A0 (en) Crystalline rosuvastatin calcium
IL201874A0 (en) Azetidine derivatives and their use as prostaglandin e2 antagonists
PL1899297T3 (pl) Zofenopryl wapnia w postaci polimorficznej c
GB2448973B (en) Gypsum based compositions
GB0715626D0 (en) Crystalline form of zofenopril calcium
PL2066173T3 (pl) Kompozycje użyteczne w rolnictwie
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists